Drugs / CD1c (BDCA-1)+ myDC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03707808 | Jan 2018 → Apr 2027 expected | malignant soft tissue neoplasm | University Hospital Brussels | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD1c (BDCA-1)+ myDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03707808 ↗ |
| Modality | Cell therapy | “The investigators consider that the isolation represents a non-substantial manipulation of this somatic cell therapy product.” NCT03707808 ↗ |